ACC/AHA Guidelines Predict Cardiac Risk More Accurately Than ATP-III Guidelines

Among patients at intermediate risk, ACC/AHA criteria are particularly good at discriminating those most likely to benefit from statin therapy.

The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines on statin use to prevent atherosclerotic cardiovascular disease (ASCVD) have been criticized for overestimating ASCVD risk, especially in older patients (NEJM JW Gen Med Apr 15 2015 and Ann Intern Med 2015; 162:266). To assess the guidelines' accuracy, investigators used data from the Framingham Heart Study to determine risk for incident ASCVD in patients eligible for statin therapy according to ACC/AHA guidelines versus those eligible under 2004 Third Adult Treatment Panel (ATP-III) guidelines. The study involved 2435 statin-naive adults (mean age, 51) without known ASCVD who underwent risk-factor assessment at baseline and were followed for a median 9 …

Reviewing Author

Thomas L. Schwenk, MD

Disclosures

Editorial BoardsUpToDate

Thomas L. Schwenk, MD

Disclosures

Editorial BoardsUpToDate

ACC/AHA Guidelines Predict Cardiac Risk More Accurately Than ATP-III Guidelines

Topics

Reviewing Author